| Overview |
| bs-11463R |
| Liprin alpha 1/PPFIA1 Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Liprin alpha 1 |
| 141-190/1202 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| LAR interacting protein 1; LIP 1; LIP.1; LIP1; LIPRIN; MGC26800; PPFIA 1; PPFIA1; Protein tyrosine phosphatase receptor type f polypeptide PTPRF interacting protein liprin alpha 1; Protein tyrosine phosphatase receptor type f polypeptide interacting protein alpha 1; PTPRF interacting protein alpha 1; LIPA1_HUMAN. |
| Liprins interact with members of the leukocyte common antigen-related (LAR) family of transmembrane protein tyrosine phosphatases, which are implicated in axon guidance and mammary gland development. Liprins are multivalent proteins that form complex structures and act as scaffolds for the recruitment and anchoring of LAR phosphatases. Based on sequence similarities and binding characteristics, liprins are subdivided into Alpha and Beta liprins. Both Alpha and Beta liprins homodimerize via their N-terminal, coiled-coil regions. Liprin Alpha1 is a ubiquitously expressed protein that interacts with the tumor suppressor ING4 to regulate cell migration and possibly prevent metastasis. The interaction between LAR and Liprin Alpha1 can be weakened by treatment of Liprin ? with calf intestinal phosphatase. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz